By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel's net takeaway is that Waystar's valuation at 11x adjusted cash flow with 22% revenue growth is questionable due to high debt levels, potential margin compression, and risks from payer consolidation and AI claims' proprietary nature.
Risk: High debt levels and potential margin compression in a 'higher-for-longer' rate environment
Opportunity: Potential re-rating if Waystar can maintain its 20%+ growth rate and prove its AI claims are proprietary
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Discovery Fund”. A copy of the letter can be downloaded here. It was a difficult quarter for Baron Discovery Fund, both on an absolute and relative basis. The Fund declined 10.65% (Institutional Shares) in the quarter, compared to the Russell 2000 Growth Index’s return of -2.81%. The underperformance of 7.88% was primarily attributed to sectors such as Information Technology, Consumer Discretionary, Health Care, and Industrials, along with a lack of exposure to Energy. The Fund sees the current SaaS-pocalypse as an opportunity to invest in compelling prospects among software companies that possess robust and sustainable competitive advantages. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Baron Discovery Fund highlighted stocks like Waystar Holding Corp. (NASDAQ:WAY). Waystar Holding Corp. (NASDAQ:WAY) is a technology company that provides software solutions for healthcare payments. On May 7, 2026, Waystar Holding Corp. (NASDAQ:WAY) closed at $21.01 per share. One-month return of Waystar Holding Corp. (NASDAQ:WAY) was -2.28%, and its shares lost 47.49% over the past 52 weeks. Waystar Holding Corp. (NASDAQ:WAY) has a market capitalization of $4.03 billion.
Baron Discovery Fund stated the following regarding Waystar Holding Corp. (NASDAQ:WAY) in its Q1 2026 investor letter:
"Finally, we added to
Waystar Holding Corp. (NASDAQ:WAY), which like Heartflow has been lumped into the “AI software losers” bucket. Waystar is a provider of revenue cycle management software to health care providers. The company has an AI driven, end-to-end suite of solutions that saves clients massive amounts of working capital costs by getting claims submitted quickly and correctly, and by automating insurance appeals when necessary. At under 11 times adjusted cash flow, but growing cash flow in the low teens, we believe the company is competitively advantaged and very cheap."
Waystar Holding Corp. (NASDAQ:WAY) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 46 hedge fund portfolios held Waystar Holding Corp. (NASDAQ:WAY) at the end of the fourth quarter, compared to 47 in the previous quarter. In Q1 2026, Waystar Holding Corp. (NASDAQ:WAY) reported revenue of $314 million, representing 22% year-over-year growth. While we acknowledge the potential of Waystar Holding Corp. (NASDAQ:WAY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Four leading AI models discuss this article
"Waystar’s 22% revenue growth combined with a sub-11x cash flow multiple presents a compelling asymmetric risk-reward profile if the company demonstrates sustained margin expansion in 2026."
Baron’s thesis on Waystar (WAY) hinges on a valuation disconnect—trading at under 11x adjusted cash flow while delivering 22% top-line growth. This suggests a classic 'value trap' versus 'undervalued gem' debate. While the revenue cycle management (RCM) sector is defensive, the market is clearly punishing WAY for its high debt load and the broader 'SaaS-pocalypse' multiple compression. If WAY can maintain its 20%+ growth rate, the current $4 billion market cap is undeniably cheap. However, investors must scrutinize whether their AI automation claims are truly proprietary or merely commoditized features that will face margin pressure from larger, integrated legacy EHR players.
The market is likely pricing in a 'race to the bottom' for RCM software pricing, where Waystar’s AI-driven efficiency gains are captured by insurance payers rather than retained as profit by the company.
"WAY's <11x adjusted cash flow multiple versus low-teens growth and 22% revenue beats undervalues its AI-enhanced RCM moat in a defensive healthcare vertical."
Baron Discovery Fund's addition to Waystar (WAY) amid the SaaS selloff highlights a compelling value play in healthcare revenue cycle management (RCM) software. At <11x adjusted cash flow with low-teens CF growth and Q1 revenue up 22% YoY to $314M, WAY trades at a discount to peers despite AI-driven efficiencies in claims processing and appeals. The fund's thesis counters the 'AI software losers' narrative, positioning WAY's sticky hospital client base (high switching costs) for re-rating if execution holds. Down 47% over 52 weeks to $21/share ($4B mkt cap), this smells like oversold opportunity in a sector resilient to macro pressures.
Healthcare RCM faces intensifying regulatory scrutiny (e.g., CMS changes on prior auth) and competition from incumbents like R1 RCM or Optum, potentially eroding WAY's moat if AI fails to deliver promised cash flow acceleration amid post-IPO integration hiccups.
"WAY's valuation is only compelling if adjusted cash flow growth actually materializes at low-teens rates; the article provides no Q1 2026 guidance or forward cash flow estimates to validate Baron's thesis."
Baron's WAY thesis hinges on a valuation arbitrage: 11x adjusted cash flow against low-teens cash flow growth looks cheap versus SaaS comps. But the 52-week -47% drawdown and Q1 2026 guidance absence are red flags. Revenue grew 22% YoY—solid—but the article doesn't disclose adjusted cash flow growth rates, margins, or free cash flow conversion. 'AI software losers bucket' suggests narrative risk persists regardless of fundamentals. The real question: is WAY cheap because it's mispriced, or because healthcare RCM software faces structural headwinds (payer consolidation, regulatory pressure, margin compression)? Baron's contrarian positioning is intellectually honest, but the valuation math only works if cash flow growth sustains.
Baron added to a stock down 47% in 12 months during a 'difficult quarter' for the fund itself—classic value trap behavior. If adjusted cash flow isn't actually growing in the low teens (unverified in article), the 11x multiple is a mirage, not a bargain.
"WAY's cheap-appearing multiple rests on adjusted cash flow that may not be durable; real cash generation and durable growth could disappoint if payer adoption slows, sales cycles remain long, or margin headwinds emerge."
Waystar is pitched as a cheap, AI-enabled SaaS play in healthcare payments, trading ~11x adjusted cash flow with low-teens cash-flow growth amid 22% revenue expansion (Q1 2026). The headline risk is that 'adjusted cash flow' can hide working-capital swings and one-off items; healthcare IT faces long, procurement-heavy sales cycles, customer concentration, and regulatory/cybersecurity costs. AI marketing claims may not translate into durable competitive advantage against entrenched incumbents. Valuation could re-rate downward if payer adoption stalls, margins compress, or if growth slows as contracts rollover and competition intensifies. The tariff/onshoring plug is speculative policy risk that may never materialize.
If WAY truly delivers meaningful, scalable AI-driven savings and maintains high retention, the moat could be durable and the stock could re-rate, making the current multiple look conservatively low.
"Waystar's high debt load makes its current valuation a trap, as interest expenses will likely erode cash flow regardless of operational AI gains."
Claude hits the nail on the head regarding the 'adjusted' metrics. Everyone is ignoring the elephant in the room: Waystar’s leverage. With a debt-heavy balance sheet, high interest expenses in a 'higher-for-longer' rate environment will cannibalize that adjusted cash flow regardless of AI efficiency. If they aren't deleveraging, that 11x multiple is a trap, not a bargain. The market isn't just punishing SaaS multiples; it's pricing in bankruptcy risk or severe equity dilution for over-leveraged tech.
"Gemini's bankruptcy claim lacks evidence; payer-driven disintermediation is the real unpriced risk."
Gemini escalates leverage to 'bankruptcy risk'—unsubstantiated hyperbole absent covenant breaches or maturity cliffs in filings. With 22% revenue growth and defensive RCM cash flows, debt service looks covered short-term. Panel misses key connection: payer consolidation (flagged by Claude) amplifies regulatory risk, where top payers could bypass WAY's AI tools via in-house builds, eroding the moat Baron bets on.
"Leverage + higher rates = margin compression risk that overshadows revenue growth, making the 11x multiple vulnerable regardless of AI execution."
Grok dismisses Gemini's leverage concern as 'hyperbole,' but doesn't address the actual risk: in a 'higher-for-longer' rate environment, even serviceable debt becomes a drag on FCF conversion and equity returns. The 22% revenue growth is nominal, not real—if margins compress under rate pressure, that growth doesn't translate to shareholder value. Grok's payer in-house build risk is real, but it's secondary to whether WAY's cash flow math holds at current rates.
"AI ROI may take longer to materialize than revenue growth implies, risking delayed cash flow realization and a weaker near-term multiple."
New risk: time-to-value in WAY's AI-enabled RCM. Even with 22% revenue growth, implement cycles, onboarding, and integration costs can push cash flow realization out beyond near-term periods. If customers delay deployments or require custom builds, adjusted cash flow may lag earnings power, undermining the 11x multiple thesis. This isn't captured by leverage talk or payer-consolidation narratives yet, and could cap near-term multiple re-rating.
The panel's net takeaway is that Waystar's valuation at 11x adjusted cash flow with 22% revenue growth is questionable due to high debt levels, potential margin compression, and risks from payer consolidation and AI claims' proprietary nature.
Potential re-rating if Waystar can maintain its 20%+ growth rate and prove its AI claims are proprietary
High debt levels and potential margin compression in a 'higher-for-longer' rate environment